0
Abstract: Slide Presentations |

ERRP, A NOVEL ENDOGENOUS PEPTIDE AND AN EGFR TARGETING AGENT, INHIBITS PROLIFERATION OF SMALL CELL LUNG CANCER AS EFFECTIVELY AS IT INHIBITS NON-SMALL CELL LUNG CANCERS FREE TO VIEW

Ahmed J. Khan, MD*; Stephanie Gruenloh, BS; Rahul Nanchal, MD; Meetha Medhora, PhD; Elizabeth Jacobs, MD
Author and Funding Information

Medical College of Wisconsin, Milwaukee, WI


Chest


Chest. 2007;132(4_MeetingAbstracts):458a. doi:10.1378/chest.132.4_MeetingAbstracts.458a
Text Size: A A A
Published online

Abstract

PURPOSE: Some inhibitors of Epidermal-Growth-Factor-receptor (EGFR) are FDA approved for clinical use against non-small-cell-lung-cancer(NSCLC) while more are in bench-research and clinical-trial stages. Data on the role of EGFR targetted therapy on Small-Cell-Lung-Cancer (SCLC) is limited. We studied the effect of a novel endogenous peptide, ERRP(EGF Receptor related Peptide), on in-vitro proliferation of SCLC and NSCLC cell-lines.

METHODS: Human NSCLC cell-line NCI-H522 and differential HER-expressing Human SCLC cell line NCI-H526, NCI-H69 and NCI-H146 were cultured in RPMI/10% fetal-bovine-serum/pen-strep media. 5000 Cells were plated in 96-well plates,incubated for 48 hours, washed in PBS, and subsequently incubated for 48 more hours in low-serum medium containing different dose of ERRP. Cells were then incubated with MTT (1 mg/mL) at 37°C for 2 hours and then with DMSO at room temperature for 1 hour. Spectrophotometric absorbance of the samples was determined by Microplate Reader. Results were plotted as means ± SD of three separate experiments having six determinations per experiment for each experimental condition.Western blot analysis was done to study comparatie HER receptor expression.

RESULTS: After analysis of MTT assay cell viability data, it was shown that there was a dose dependent inhibition of proliferation of the NSCLC as well all the three SCLC cell lines after they were exposed to ERRP for 48 hours. In case of NSCLC NCI H522 cell lines, the there was a drop of 30%, 60% and 80% respectively with 2.5 ug/ml, 5 ug/ml and 10 ug/ml dose of ERRP. There were almost identical rates of decrease in viable cells in plates containing SCLC cell lines NCI H69, NCI H146 and NCI H526 cell lines.

CONCLUSION: The ERRP-induced decrease in number of cells is due to inhibition of cell proliferation. This has been confirmed in earlier studies on EGFR-free Fibroblast cells. Our data shows that ERRP has significant inhibitory effect on SCLC-cell-lines irrespective of EGFR-expression. The degree of inhibition was nearly identical to that on NSCLC-cell-lines.

CLINICAL IMPLICATIONS: Addition of EGFR-inhibiting-agents as therapeutic option against SCLC has potential for improving Small-Cell-Lung-Cancer-mortality.

DISCLOSURE: Ahmed Khan, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, October 23, 2007

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543